Skip Navigation

COVID-19 Update

We continue to monitor COVID-19 cases in our area and providers will notify you if there are scheduling changes. Please continue to call your providers with health concerns. We are providing in-person care and telemedicine appointments.

Learn about our expanded patient care options and visitor guidelines.

General Information | Self-Checker | Donate and Lend Support | Staff Appreciation | Get Email Alerts

 

The Richman Family Precision Medicine Center of Excellence in Alzheimer’s Disease (AD) is a unique translational project aimed at characterizing a finite set of therapeutically relevant AD subtypes taking into account known genetic factors, biologic “endophenotypes” assessed by blood, cerebrospinal fluid (CSF), or brain imaging, as well as aspects of clinical phenotype.

The ultimate goal is to translate this knowledge into clinical care by defining patients who respond optimally to currently available and emerging therapies. Subtyping will also lead to identifying new therapeutic targets based on refined and granular understanding of disease mechanisms.

 

Alzheimer's and Dementia Research

Questions we're asking that inform us on how to best care for patients include:

geometric shapes icon

Big Data Power

Which sub populations are more at-risk for cognitive decline and fast disease progression?

stethoscope icon

Scaling Evidenced-Based Care

How can the current quality care be made available to all persons with dementia throughout Johns Hopkins?

pills icon

Closing the Loop

How can we fast track the research from clinic to test tube and back to the clinic with biomarkers for subtyping and for advancing therapeutics?

MRI icon

Innovation - Brain Scans

How can existing brain MRI methods be refined  for early detection, prognosis, or predicting response to  available medications?

needle icon

Innovation - New Blood Test

Can novel blood tests based on “exosomes” be used to learn about what’s going on in the brain so as to stage the AD brain disease and monitor treatment response?

DNA icon

Innovation - Stem Cell Models

Can blood derived stems cells be used to test whether individual patients will be helped by available and emerging medication treatments?

Clinical Trials

The Richman Family Precision Medicine Center of Excellence in Alzheimer’s Disease facilitates access to several clinical trials conducted as part of the Johns Hopkins Memory and Alzheimer's Treatment Center (MATC) or the NIA-funded Johns Hopkins Alzheimer's Disease Research Center (ADRC). These studies aim to identify even better therapies and treatment options while gaining further insight into the best care now and in the future.

 

Patient Care for Alzheimer's Disease 

The research we do directly impacts the treatment options available to our patients. Find out more about patient care for Alzheimer's Disease.

The Johns Hopkins Memory and Alzheimer's Treatment Center
The Johns Hopkins Bayview Medical Center
5300 Alpha Commons Drive, Floor 4
Baltimore, MD 21224

 
 
 
 

 

Faculty

Faculty Spotlight


Dimitrios Kapogiannis, M.D.

Dimitrios Kapogiannis, M.D. is Chief of the Human Neuroscience Unit at the National Institute of Aging and adjunct Associate Professor in the Department of Neurology at Johns Hopkins. He is a clinician-scientist, ABPN-certified in Neurology and UCNS-certified in Behavioral Neurology. His translational laboratory focuses on discovering novel biomarkers for preclinical diagnosis and therapeutic response in Alzheimer's and other neurodegenerative diseases. He has pioneered deriving Extracellular Vesicles enriched for neuronal and astrocytic origin from peripheral blood.

Meet Dr. Kapogiannis

Charitable Giving

Support diagnosis and treatment advancements and discoveries by Johns Hopkins Scientists.

back to top button